A Randomized Placebo-Controlled Safety and Pharmacodynamic Study of KB002, an Anti-GM-CSF Monoclonal Antibody, in Patients with Persistent Symptomatic Asthma

Trial Profile

A Randomized Placebo-Controlled Safety and Pharmacodynamic Study of KB002, an Anti-GM-CSF Monoclonal Antibody, in Patients with Persistent Symptomatic Asthma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs KB 002 (Primary)
  • Indications Asthma
  • Focus Adverse reactions
  • Sponsors Humanigen; KaloBios Pharmaceuticals
  • Most Recent Events

    • 07 Aug 2017 According to a Humanigen media release, KaloBios Pharmaceuticals changed its name to Humanigen.
    • 22 May 2013 Results presented at the 109th International Conference of the American Thoracic Society.
    • 26 Feb 2013 Results presented at the 69th Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top